Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
GQ1001 / GeneQuantum Healthcare
GRACE, NCT05575804: GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer	Recruiting	1/2	75	RoW	GQ1001+pyrotinib, pyrotinib+capecitabine	Fudan University, GeneQuantum Healthcare (Suzhou) Co., Ltd.	Advanced/ Metastatic Her-2 Positive Breast Cancer	01/25	01/25
ACTRN12620000592943: Phase I Dose Finding Study in Patients with HER2-Positive Advanced Solid Tumors	Recruiting	1	13			Conjugate Light (Australia) Pty Ltd, Conjugate Light (Australia) Pty Ltd	HER2-Positive Advanced Solid Tumors
NCT04450732 / ACTRN12620000592943: Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors	Recruiting	1	96	US, RoW	GQ1001	GeneQuantum Healthcare (Suzhou) Co., Ltd., Conjugate Light (Australia) Pty Ltd	HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer, HER2-Positive Salivary Gland Carcinomas, HER2-Positive Advanced Solid Tumor	03/24	05/24